Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
Firefly Neuroscience (NASDAQ: AIFF) has announced advancements in its AI-powered Brain Network Analytics (BNA™) technology following successful research collaborations with Takeda and Novartis. The collaborations demonstrate the value of Firefly's AI-based technology in providing objective measures for neuroscience drug development.
CEO Jon Olsen highlighted that BNA™ technology enables pharmaceutical companies to enhance trial design, accelerate drug candidate advancement, and improve clinical outcomes. The technology offers tools for improved patient and dose selection, potentially reducing costs and development time in CNS drug development.
Firefly aims to expand partnerships with neuroscience pharmaceutical companies, leveraging its unique database and technology. The company believes that electrophysiology-based biomarkers like BNA represent a significant opportunity for neuroscience drug development, especially in addressing concerns about the high cost of new drugs and identifying patients most likely to benefit from them.
Firefly Neuroscience (NASDAQ: AIFF) ha annunciato dei progressi nella sua tecnologia di Analisi delle Reti Cerebrali (BNA™) potenziata dall'IA, grazie a collaborazioni di ricerca di successo con Takeda e Novartis. Queste collaborazioni dimostrano il valore della tecnologia basata sull'IA di Firefly nel fornire misure oggettive per lo sviluppo di farmaci nel campo delle neuroscienze.
Il CEO Jon Olsen ha sottolineato che la tecnologia BNA™ consente alle aziende farmaceutiche di migliorare la progettazione degli studi clinici, accelerare l'avanzamento dei candidati farmaci e migliorare gli esiti clinici. La tecnologia offre strumenti per una selezione migliore dei pazienti e delle dosi, potenzialmente riducendo costi e tempi di sviluppo nella creazione di farmaci per il sistema nervoso centrale.
Firefly mira ad espandere le partnership con le aziende farmaceutiche nel campo delle neuroscienze, sfruttando la sua banca dati unica e la tecnologia. L'azienda crede che i biomarcatori basati sull'elettrofisiologia, come BNA, rappresentino un'opportunità significativa per lo sviluppo di farmaci nel campo delle neuroscienze, specialmente per affrontare le preoccupazioni riguardo ai costi elevati di nuovi farmaci e identificare i pazienti più propensi a beneficiarne.
Firefly Neuroscience (NASDAQ: AIFF) ha anunciado avances en su tecnología de Análisis de Redes Cerebrales (BNA™) impulsada por IA tras colaboraciones de investigación exitosas con Takeda y Novartis. Estas colaboraciones demuestran el valor de la tecnología basada en IA de Firefly para proporcionar medidas objetivas en el desarrollo de fármacos en neurociencias.
El CEO Jon Olsen destacó que la tecnología BNA™ permite a las empresas farmacéuticas mejorar el diseño de ensayos, acelerar el avance de candidatos a medicamentos y mejorar los resultados clínicos. La tecnología ofrece herramientas para una mejor selección de pacientes y dosis, lo que podría reducir costos y tiempos de desarrollo en el desarrollo de fármacos para el sistema nervioso central.
Firefly busca expandir asociaciones con empresas farmacéuticas de neurociencia, aprovechando su base de datos única y tecnología. La compañía cree que los biomarcadores basados en electrofisiología como BNA representan una oportunidad significativa para el desarrollo de fármacos en neurociencias, especialmente para abordar las preocupaciones sobre el alto costo de los nuevos medicamentos e identificar a los pacientes que son más propensos a beneficiarse de ellos.
파이어플라이 뉴로사이언스 (NASDAQ: AIFF)는 타케다 및 노바티스와의 성공적인 연구 협력을 통해 AI 기반의 뇌 네트워크 분석 (BNA™) 기술에서 발전을 발표했습니다. 이러한 협력은 파이어플라이의 AI 기반 기술이 신경과학 약물 개발을 위한 객관적인 척도를 제공하는데 얼마나 가치 있는지를 보여줍니다.
CEO 존 올센은 BNA™ 기술이 제약 회사들이 시험 설계를 개선하고, 약물 후보의 진행을 가속화하며, 임상 결과를 향상시키는데 도움을 준다고 강조했습니다. 이 기술은 보다 나은 환자와 용량 선택을 위한 도구를 제공하여, CNS 약물 개발의 비용과 개발 시간을 줄일 수 있는 가능성을 가지고 있습니다.
파이어플라이는 독창적인 데이터베이스와 기술을 활용하여 신경과학 제약 회사들과의 파트너십을 확대할 계획입니다. 이 회사는 BNA와 같은 전기생리학 기반 바이오마커가 신경과학 약물 개발에 중대한 기회를 제공하며, 특히 신약의 높은 비용에 대한 우려를 해결하고, 혜택을 받을 가능성이 가장 높은 환자를 식별하는 데 중요하다고 믿습니다.
Firefly Neuroscience (NASDAQ: AIFF) a annoncé des avancées dans sa technologie d'Analyse de Réseaux Cérébraux (BNA™) propulsée par l'IA, suite à des collaborations de recherche fructueuses avec Takeda et Novartis. Ces collaborations démontrent la valeur de la technologie basée sur l'IA de Firefly pour fournir des mesures objectives dans le développement de médicaments en neurosciences.
Le PDG Jon Olsen a souligné que la technologie BNA™ permet aux entreprises pharmaceutiques d'améliorer la conception des essais cliniques, d'accélérer l'avancement des candidats médicaments et d'améliorer les résultats cliniques. La technologie offre des outils pour une meilleure sélection des patients et des doses, réduisant potentiellement les coûts et le temps de développement dans le domaine des médicaments pour le système nerveux central.
Firefly vise à élargir ses partenariats avec des entreprises pharmaceutiques en neurosciences, en s'appuyant sur sa base de données unique et sa technologie. L'entreprise croit que les biomarqueurs basés sur l'électrophysiologie comme BNA représentent une opportunité significative pour le développement de médicaments en neurosciences, en particulier pour répondre aux préoccupations concernant le coût élevé des nouveaux médicaments et identifier les patients les plus susceptibles d'en bénéficier.
Firefly Neuroscience (NASDAQ: AIFF) hat Fortschritte in seiner KI-gestützten Technologie der Gehirnnetzwerkanalyse (BNA™) nach erfolgreichen Forschungskooperationen mit Takeda und Novartis angekündigt. Diese Kooperationen zeigen den Wert der KI-basierten Technologie von Firefly zur Bereitstellung objektiver Messgrößen für die Entwicklung von Arzneimitteln in der Neurowissenschaft.
CEO Jon Olsen hob hervor, dass die BNA™-Technologie es Pharmaunternehmen ermöglicht, das Studiendesign zu verbessern, den Fortschritt von Arzneimittelkandidaten zu beschleunigen und klinische Ergebnisse zu verbessern. Die Technologie bietet Werkzeuge für eine verbesserte Patienten- und Dosisauswahl, was die Kosten und die Entwicklungszeit in der CNS-Arzneimittelentwicklung potenziell senken könnte.
Firefly beabsichtigt, Partnerschaften mit Pharmaunternehmen im Bereich Neurowissenschaften auszubauen und dabei auf seine einzigartige Datenbank und Technologie zurückzugreifen. Das Unternehmen glaubt, dass elektrophysiologisch basierte Biomarker wie BNA eine bedeutende Chance für die Entwicklung von Arzneimitteln in der Neurowissenschaft darstellen, insbesondere um Bedenken hinsichtlich der hohen Kosten neuer Medikamente zu adressieren und Patienten zu identifizieren, die am wahrscheinlichsten davon profitieren.
- Successful research collaborations with major pharmaceutical companies Takeda and Novartis
- BNA™ technology provides objective measures for neuroscience drug development
- Potential to reduce costs and accelerate drug development in CNS field
- Opportunity to expand partnerships with neuroscience pharmaceutical companies
- None.
Insights
Firefly's advancement of AI-driven BNA™ technology marks a significant leap in neuroscience drug development. The successful collaborations with Takeda and Novartis, two pharmaceutical giants, validate the technology's potential. BNA™ provides objective measures of brain activity, which can streamline clinical trials, potentially reducing both time and costs in drug development.
The technology's ability to precisely measure drug effects on the brain and identify responsive patients is particularly noteworthy. This could lead to more targeted therapies and improved clinical outcomes. Moreover, in an era of increasing healthcare costs, BNA™'s potential to identify patients most likely to benefit from expensive new drugs addresses a critical need in the market.
However, it's important to note that while promising, the technology is still in the research phase. Its full impact on drug development timelines and success rates remains to be seen in larger-scale applications.
Firefly's collaborations with Takeda and Novartis significantly enhance its market position and growth potential. These partnerships not only validate Firefly's technology but also open doors for future revenue streams through expanded collaborations in the
The company's focus on reducing drug development costs and time could make it an attractive partner for other pharma companies, potentially leading to more lucrative deals. However, investors should note that Firefly's financial impact may not be immediate, as drug development cycles are typically long.
The emphasis on cost-effective patient selection for expensive new drugs aligns well with current healthcare trends, potentially making Firefly's technology more appealing to insurers and healthcare providers. This could create additional revenue opportunities beyond pharmaceutical partnerships.
Firefly's BNA™ technology represents a compelling intersection of AI and neuroscience. The use of AI to analyze brain activity and provide objective measures for drug development is at the cutting edge of healthtech innovation. This approach could potentially revolutionize how CNS drugs are developed and tested.
The technology's ability to enhance patient and dose selection is particularly noteworthy. By leveraging AI to analyze complex brain activity data, Firefly can provide insights that were previously difficult or impossible to obtain. This could lead to more personalized treatment approaches in neurology and psychiatry.
However, as with any AI-based health technology, questions about data privacy, algorithm transparency and regulatory approval processes will need to be addressed. The success of BNA™ will depend not just on its technical capabilities, but also on how well it navigates these broader issues in the healthcare AI landscape.
TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders, today announced advancing its artificial intelligence-powered Brain Network Analytics (BNA™) technology after successful research collaborations with Takeda Pharmaceutical Company Limited (“Takeda”) and Novartis, two global leaders in pharmaceutical R&D, illustrating the value of Firefly’s AI-based technology in providing objective measures in neuroscience drug development.
“Our collaborations with Takeda and Novartis mark a pivotal step in accelerating drug development,” said Jon Olsen, Firefly’s CEO. “By using our BNA™ technology, pharmaceutical companies can leverage the additional objective measures of brain activity to enhance the design of future trials and advance their drug candidates faster toward regulatory approval. Additionally, integrating Firefly's BNA™ technology into neuroscience drug development allows researchers to reduce costs and time by precisely measuring drug effects on the brain and identifying patients most likely to respond, leading to improved clinical outcomes.”
Incorporating Firefly’s BNA™ technology into CNS drug development provides biotechnology and pharma companies with tools to enhance patient and dose selection, thus reducing cost and accelerating drug development. Firefly intends to continue leveraging its unique database and technology to expand its partnerships with neuroscience pharmaceutical companies, building on its collaborations with industry leaders like Novartis and Takeda.
“Many new drugs being developed are expensive, and there is considerable resistance from healthcare providers, governments, and insurers to absorb the high cost of new drugs without knowing who is most likely to benefit from the drug,” continued Mr. Olsen. “Firefly believes that electrophysiology-based biomarkers, like BNA, represent a significant opportunity for neuroscience drug development companies.”
About Firefly
Firefly (NASDAQ: AIFF) is an Artificial Intelligence (“AI”) company developing innovative solutions that improve brain health outcomes for patients with neurological and mental disorders. Firefly’s FDA-510(k) cleared Brain Network Analytics (BNA™) technology revolutionizes diagnostic and treatment monitoring methods for conditions such as depression, dementia, anxiety disorders, concussions, and ADHD. Over the past 15 years, Firefly has built a comprehensive database of brain wave tests, securing patent protection, and achieving FDA clearance. The Company is now launching BNA™ commercially, targeting pharmaceutical companies engaged in drug research and clinical trials, as well as medical practitioners for clinical use.
Brain Network Analytics was developed using artificial intelligence and machine learning on Firefly’s extensive proprietary database of standardized, high-definition longitudinal electroencephalograms (EEGs) of over 17,000 patients representing twelve disorders, as well as clinically normal patients. BNA™, in conjunction with an FDA-cleared EEG system, can provide clinicians with comprehensive insights into brain function. These insights can enhance a clinician’s ability to accurately diagnose mental and cognitive disorders and to evaluate what therapy and/or drug is best suited to optimize a patient’s outcome.
Please visit https://fireflyneuro.com/ for more information.
Forward-Looking Statements
Certain statements in this press release and the information incorporated herein by reference may constitute “forward-looking statements” for purposes of the federal securities laws concerning Firefly. These forward-looking statements include express or implied statements relating to Firefly’s management teams’ expectations, hopes, beliefs, intentions, or strategies regarding the future. In addition, any statements that refer to projections, forecasts or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. The words “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intends,” “may,” “might,” “plan,” “possible,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements are based on current expectations and beliefs concerning future developments and their potential effects. There can be no assurance that future developments affecting Firefly will be those that have been anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond Firefly’s control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to: risks related to development and commercialization of BNA™ technology; risks related to Firefly’s ability to recognize the anticipated benefits of the merger (the “Merger”) with WaveDancer, Inc. (“WaveDancer”); risks related to Firefly’s ability to correctly estimate its operating expenses and expenses associated with the Merger and other events and unanticipated spending and costs that could reduce Firefly’s cash resources; the ability of Firefly to protect its intellectual property rights; competitive responses to the business combination; unexpected costs, charges or expenses resulting from the Merger; potential adverse reactions or changes to business relationships resulting from the completion of the Merger; legislative, regulatory, political and economic developments; and those factors described under the heading “Risk Factors” in the in the registration statement on Form S-4 filed by WaveDancer with the Securities and Exchange Commission on January 22, 2024, as amended, and declared effective on February 6, 2024. Should one or more of these risks or uncertainties materialize, or should any of Firefly’s assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. It is not possible to predict or identify all such risks. Forward-looking statements included in this press release only speak as of the date they are made, and Firefly does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Investor Contact
KCSA Strategic Communications
Valter Pinto or Jack Perkins
(212) 896-1254
Firefly@KCSA.com
Media Contact
KCSA Strategic Communications
Raquel Cona, Vice President
(516) 779-2630
Rcona@KCSA.com
FAQ
What is Firefly Neuroscience's stock symbol?
What is Firefly Neuroscience's BNA™ technology?
Which pharmaceutical companies has Firefly Neuroscience collaborated with?
How can BNA™ technology benefit pharmaceutical companies?
